Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
Rhea-AI Summary
Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biotechnology company, has scheduled its fourth quarter 2024 financial results conference call and webcast for Thursday, March 27, 2025, at 4:30 PM ET. The company will discuss its business progress and financial performance for the quarter ended December 31, 2024.
Investors can access the conference through US dial-in (1-877-407-0792) or International dial-in (1-201-689-8263) with conference code 13751458. A webcast replay will be available in the Investors section of Relmada's website.
Positive
- None.
Negative
- None.
News Market Reaction – RLMD
On the day this news was published, RLMD declined 4.21%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024.
Conference Call and Webcast Information:
- Date: Thursday, March 27, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Conference: 13751458
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette’s Syndrome into further studies.
For more information, visit www.relmada.com.
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When will Relmada Therapeutics (RLMD) release Q4 2024 earnings?
How can investors access RLMD's Q4 2024 earnings call?
Where can I find the replay of RLMD's Q4 2024 earnings webcast?
What period will RLMD's upcoming earnings report cover?
